12 results about "Telomere" patented technology

The present disclosure relates, according to some embodiments, to telomere resolvases (e.g., TelA variants) having a turnover number over 1.

The present invention relates to a novel compounds for use in treatment or prevention of cancer, in particular to use of said compounds as an inhibitors of interactions between TRF1-TIN2 or TRF2-TIN2 telomeric proteins.

An object of the present invention is to provide a novel use of fermented papaya preparation. A composition of the present invention is a composition for elongating telomeres comprising fermented papaya preparation as an active ingredient.

Disclosed are use of a circRNA molecule as a diagnostic marker in a cell senescence diagnosis kit, and use thereof as a treatment target for cell senescence. The present invention finds that circHERC1 is lowly expressed in both cell models of natural senescence and induced senescence. Overexpression of circHERC1 in endothelial cells can improve the proliferation capacity of the endothelial cells, effectively extend the telomere length of the cells, activate telomerase, reduce the β-galactosidase positive rate of the cells, and reduce the expression of all senescence-associated proteins. Introduction of exogenous circHERC1 into mice can effectively delay the senescence of various organs and the shortening of telomeres in aged mice and reduce the β-galactosidase positive rates of various organs of aged mice.

The application relates to the technical field of biological medicine, and particularly discloses a telomere-related gene marker for hepatocellular carcinoma prognosis prediction, a prognosis risk scoring model and application thereof. The application integrates the expression profile of a telomere-related gene in a TCGA-LIHC queue and clinical data, uses consistent clustering analysis to identify two telomere subtypes with significant survival difference, and further uses LASSO-Cox regression to construct a hepatocellular carcinoma prognosis risk scoring model containing 20 characteristic genes. The model shows excellent prediction performance in an internal training set and an external validation set, and can accurately distinguish high-risk and low-risk patients. The risk score is closely related to a tumor immune microenvironment, and high-risk patients show an immune inhibition state, such as reduced CD8+ T cell infiltration, which provides a basis for predicting the response of patients to an immune checkpoint inhibitor.

The present application relates to the field of microbial technology, and particularly relates to the application of AKK bacteria and products thereof in anti-aging and / or anti-oxidation. The preservation number of the AKK bacteria is CGMCC No. 20954, and the strain is preferably used in a pasteurized form. Through three kinds of zebrafish model experiments, it is proved that the strain can effectively improve cell aging, specifically, the telomere length is improved, the expression amount of anti-aging gene spns1 is enhanced, and the symptoms of muscle atrophy and cognitive impairment caused by aging are obviously improved. In particular, the minimum effective amount of the strain in the water body for feeding zebrafish is 250 μg / mL, and the minimum effective amount in the human body is 30 billion AFU per person per day. The present application provides a clear strain source and dosage basis for developing a multi-dimensional and systematic anti-aging functional composition.

The application discloses an aspergillus telomere-to-telomere genome assembly method, device, equipment and storage medium. The method comprises the following steps: using a plurality of sequencing sequence assembly tools to assemble target aspergillus long read genome sequencing data from scratch to obtain a first assembled genome; selecting a first assembled genome meeting a preset condition as an initial assembled genome; integrating other first assembled genomes to fill gaps between repeat regions of the initial assembled genome to obtain a second assembled genome; aligning the long read genome sequencing data to the second assembled genome, identifying abnormal coverage regions and correcting sequences to obtain a third assembled genome; aligning a reference genome to the third assembled genome, connecting and orienting different contigs, and mounting the contigs to chromosomes to obtain a fourth assembled genome; and aligning the long read genome sequencing data and short read sequencing data to the fourth assembled genome for correction to obtain an aspergillus telomere-to-telomere genome assembly result.

This invention belongs to the field of genomics and bioinformatics technology, specifically relating to a method for multidimensional quality assessment of telomere-to-telomere genomes. The method includes the following steps: preprocessing the genome data to be assessed to obtain preprocessed data; quantitatively assessing multiple core features of the preprocessed data, including accuracy, completeness, continuity, and region specificity; the region specificity includes telomere identification, centromere identification, and collinearity with a reference genome; calculating a comprehensive score based on the weighted results of the quantitative assessment of the core features, and using the comprehensive score to determine the quality of the genome to be assessed. This assessment method is specifically adapted to the core features of T2T genomes, taking into account continuity, completeness, accuracy, and region specificity, thus solving the problem that traditional methods cannot assess T2T-specific features.

The present disclosure generally relates to cancer and the treatment of cancer, including the treatment of Alternative Lengthening of Telomeres (ALT) cancers. The disclosure provides methods comprising inhibiting FANCM activity or expression, such as inhibiting FANCM's interaction with RMI and / or FANCM's ATPase activity, to inhibit the growth and / or proliferation of ALT tumor cells and / or to induce death of ATL tumor cells. The methods may be practiced on patients diagnosed with an ALT tumor.

A method for prolonging telomere length in a subject is disclosed. The method comprises administering a composition including Salvia miltiorrhiza extract, wheat α-amylase inhibitor, and probiotic powder. Administration of the composition prolongs telomere length and provides cellular effects associated with prolonged telomere length, such as a reduction in telomere-associated cellular age.

The present disclosure relates to methods of directly measuring absolute length of individual telomeres without any PCR amplification or fluorescent probe hybridization. This method can be performed in a high-throughput 96-well plate format. The disclosure provides a method of processing genomic DNA samples comprising telomeric DNA to release the telomeric DNA from the non-telomeric genomic DNA that has one end tagged with a telomere adapter and the other end ligated with a DNA barcode adapter. The telomeric DNA samples are pooled and purified prior to long-read sequencing in certain embodiments, for example via a nanopore.